Phase II multicenter trial of oral Quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/sézary syndrome.
Authors
Child, FOrtiz-Romero, P
Alvarez, R
Bagot, M
Stadler, R
Weichenthal, M
Alves, R
Quaglino, P
Beylot-Barry, M
Cowan, Richard A
Geskin, L
Pérez-Ferriols, A
Hellemans, P
Elsayed, Y
Phelps, C
Forslund, A
Kamida, M
Zinzani, P
Affiliation
St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UKIssue Date
2016-02-02
Metadata
Show full item recordAbstract
Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor.Citation
Phase II multicenter trial of oral Quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/sézary syndrome. 2016: Br J DermatolJournal
The British Journal of DermatologyDOI
10.1111/bjd.14427PubMed ID
26836950Type
ArticleLanguage
enISSN
1365-2133ae974a485f413a2113503eed53cd6c53
10.1111/bjd.14427
Scopus Count
Collections
Related articles
- Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
- Authors: Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM
- Issue date: 2013 Jan
- Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
- Authors: Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M
- Issue date: 2007 Jul 20
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
- Authors: Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators
- Issue date: 2018 Sep
- A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
- Authors: Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A, Fourneau N, Hellemans P, Elsayed Y, McClue S, Smit JW, Forslund A, Phelps C, Camm J, Evans TR, de Bono JS, Banerji U
- Issue date: 2013 Aug 1
- Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
- Authors: Kogge A, Volteau C, Saint-Jean M, Peuvrel L, Brocard A, Knol AC, Renaut JJ, Dréno B, Quéreux G
- Issue date: 2015 Jan